The purpose of this study was to understand the decision-making process used when selecting ulcer-dressing products, and to ascertain the use of health economics in the decision process. METHODS: Diverse groups of nurses highly involved in product selection were interviewed. The groups included five home-care nurses (Group 1), four acute-care nurses (Group 2), and five nurses who spent some time in LTC (Group 3). Discussions centered on 1) product switching triggering events, 2) key decision-makers, 3) mapping the decision-making process, and 4) understanding of health economics. Information about the key decision-makers at different institutions was discussed. RESULTS: 1) Performance issues were the most common reasons for product switching (66%). Product availability was the most influential factor (48%). 2) No differences in product selection criteria were observed among nurses in home, acute and long-term care. However, level and role of the nurse in each setting influenced his or her part in decision-making and product selection. 3) Product evaluation and hands-on experience were the most important elements for selecting a new or replacement product. The ability to incorporate the product into customized patient protocols was also important. 4) While nurses were somewhat familiar with the term "cost-effectiveness," most preferred the term "value." Approximately half used such information to support wound-care product decisions. Nurses were more likely to consider a product supported by a straightforward economic assessment rather than a complex decision analysis. CONCLUSION: Product selection relies heavily on trial evaluations. In addition, published health-economic studies are often too complicated. In order for health-economics research to inform decision-making in the woundcare market, studies should: 1) identify target audiences and address their decision-making needs; 2) "speak" to their audience by using terms familiar to decision-makers; and 3) present simplified diagrams, charts or models. Ontario restricted) . This study examined the effect of these policies on the use of PPI and H2-receptor antagonists (H2RA), one-year gastrointestinal (GI) resource utilization and costs. METHODS: Merged provincial databases from Quebec and Ontario were analyzed for new users of PPIs and H2RAs aged 66 or greater who began treatment between November 1, 1996 to October 31, 1997. GI related services and costs (GI drugs, physician visits, GI procedures and hospitalizations) were analyzed using multivariate regression equations on an intent-to-treat basis. RESULTS: 82,314 Ontario and 19,719 (50% sample) Quebec patients were identified as new GI drug users. The patients were similar in age, gender and length of follow-up. At the initial visit, 12.5% of Ontario and 24.1% of Quebec patients were prescribed PPIs, and 63.7% of Ontario and 50.0% of Quebec patients were prescribed H2RAs. GI hospitalization occurred in 1.7% of Ontario and 1.4% of Quebec patients (p Ͻ .01). Endoscopy rate for Ontario was 4.7% and 9.1% for Quebec (p Ͻ .001); upper GI radiography rate was 13.8% for Ontario and 9.9% for Quebec (p Ͻ .01). Factors related to PPI versus H2RA prescription included residence in Quebec (OR 2.3), initial prescription by GI specialist (OR 4.1), other specialist (OR 1.9) and endoscopy (OR 1.9). CONCLUSION: Restrictive drug policy influenced both drug and other resource utilization. In both provinces, PPI use was associated with increased disease severity and resource utilization. 
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